Results 121 to 130 of about 688 (142)

Navigating the Vaginal Milieu During Perimenopause: A Narrative Review of Physiological Changes and Clinical Implications.

J Pharm Bioallied Sci
Tiwari M, Acharya N, Mahakarkar M.
europepmc   +1 more source

Vaginal Estrogen Utilization Among Medicare Beneficiaries With Genitourinary Syndrome of Menopause.

JAMA Netw Open
Gallo K, Zhang CA, Burton C, Kamdar N, Enemchukwu EA.   +4 more
europepmc   +1 more source

Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part I: Evaluation of efficacy [PDF]

Maturitas, 2019
Objective: To evaluate the efficacy of ospemifene in treating dyspareunia associated with postmenopausal vulvo-vaginal atrophy (VVA). Methods: A structured search was carried out in PubMed-Medlin, Embase, Cochrane Controlled Trials Register databases ...
Evangelos Kontopantelis, Pierluigi Benedetti Panici, Ludovico Muzii   +2 more
exaly   +5 more sources

Effects of ospemifene on vaginal epithelium of post-menopausal women

Gynecological Endocrinology, 2017
Ospemifene is a selective estrogen receptor modulator used for the treatment of vulvo-vaginal atrophy (VVA) in post-menopausal women. No direct evidence of its effects on histological features of the human vagina has been reported.
Renato Seracchioli, Maurizio Baldassarre, Giulia Gava   +2 more
exaly   +2 more sources

Ospemifene use in postmenopausal women

Expert Opinion on Investigational Drugs, 2009
Background: Selective estrogen receptor modulators (SERMs) are structurally different compounds that interact with intracellular estrogen receptors in target organs as estrogen agonists and antagonists.
Daniela Merlotti, Ranuccio Nuti
exaly   +2 more sources

Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy [PDF]

Climacteric, 2016
Objectives To determine whether assessment of all moderate-to-severe symptoms at baseline gives a more accurate evaluation of the treatment effect of ospemifene in vulvovaginal atrophy (VVA) than the most bothersome symptom (MBS) approach.
Rossella E Nappi, Camil Castelo-Branco, T J de Villiers   +2 more
exaly   +2 more sources

Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy [PDF]

Climacteric, 2017
In the absence of a direct head-to-head study, we performed an indirect historical comparison of ospemifene 60 mg (Senshio®) vs. local vaginal estrogens in moderate or severe vulvar and vaginal atrophy (VVA).
Marco Anelli, Santiago Palacios, A O Mueck   +2 more
exaly   +2 more sources